Statins and cognitive function

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 1, 2009, Pages 1-2

  Sparks, Larry ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHOLESTEROL BLOOD LEVEL; COGNITION; DEMENTIA; DRUG USE; EDITORIAL; GENOTYPE; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL; RISK REDUCTION; COGNITIVE DEFECT; NOTE; RISK FACTOR;

ALZHEIMER DISEASE; COGNITION DISORDERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 58249089857     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.160291     Document Type: Editorial

References (25)

1. Haag MDM, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J Neurol Neurosurg Psychiatry 2009; 80:13-17.
2. Cramer C, Haan MN, Galea S, et al. Use of statin and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008; 71:344-50.
3. Sparks DL, Kryscio RJ, Sabbagh MN, et al. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008; 5:416-21.
4. Arvanitakis Z, Schneider JA. Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function and neuropathology. Neurology 2008; 70:1795-802.
5. Mainous AG, Eschenbach SL, Wells BJ, et al. Cholesterol, transferrin saturation and the development of dementia and Alzheimer's disease: Results from an 18-year population-based cohort. Fam Med 2005; 37:36-52.
6. Dufouil C, Richard F, Fievet N, et al. ApoE genotype, cholesterol level, lipid-lowering treatment and dementia. The three-city study. Neurology 2005; 64:1531-8.
7. Notkola l-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein Eepsilon4 allele, and Alzheimer's disease. Neuroepidemiol 1998; 17:14-20.
8. Kivipelto M, Helkala E-L, Hallikainen M, et al. Elevated systolic blood pressure and high cholesterol levels at midlife are risk factors for late-life dementia. Neurobiol Aging 20002; 21.S174.
9. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch Intern Med 2003; 163:1053-7.
10. Green RC, NcNagny SE, Jayakumar P, et al. Statin use is associated with reduced risk of Alzheimer's disease. Neurology 2002, 58(3 Suppl):A81.
11. Rodriguez E, Dodge H, Birzescu M, et al. Use of lipidlowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc 2002; 50:1852-6.
12. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59:223-7.
13. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59:378-84.
14. Hajjar I, Schumpert J, Hirth V, et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002; 57:M414-18
15. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease Neuroepidemiology 2004; 23:94-8.
16. Green RC, McNagny SE, Jayakumar P, et al. Statin use & the risk of Alzheimer's disease: The MIRAGE Study. Alzheimer's & Dementia 2006; 2:96-103.
17. Zandi P, Sparks DL. Khachaturian AS, et al. Do statins reduce risk of incident dementia and AD? The Cache County Study. Arch Gen Psychiatry 2005, 62:217-24.
18. Li G, Higdon R, Kukull W, et al. Statin therapy and risk of dementia in the elderly: a community based prospective cohort study. Neurology 2004; 63:1624-8.
19. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia Arch Neurol 2005; 62:1047-51.
20. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER]: a randomised controlled trial. Lancet 2002; 360:1623-30.
21. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
22. Parale GP, Baheti NN, Kulkarni PM, et al. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 2006; 62:259-65.
23. Sano M. Multi-center, randomized, double-blind, placebo-controlled trial of Simvastatin to slow the progression of Alzheimer's disease. In Alzheimer's Association International Conference on Alzheimer's Disease 2008; Abstract: T200.
24. Feldman H, Jones RW, Kivipelto M, et al. The LEADe study: A randomized, controlled trial investigating the effect of Atorvastatin on cognitive and global function in patients with mild-to-moderate Alzheimer's disease receiving background therapy of Donepezil. Neurology 2008; 71:154.
25. Sparks DL, Kivipelto M, Doody R, et al. The Atorvastatin/Donepezil in Alzheimer's Disease (LEADe) study: Effect of Atorvastatin on Alzheimer's disease progression by ApoE4 genotype. In Alzheimer's Association International Conference on Alzheimer's Disease 2008; Hot Topics abstract.